Study of HMPL-A251 for advanced HER2-positive cancers
Part of Cancer clinical trials.
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be advanced or spread and cannot be surgically removed.
- Your tumor must have a protein called HER2, which can be checked from a biopsy.
- You must have at least one tumor that can be measured on scans.
- You need to be generally active (able to take care of yourself and do light activities) and weigh at least 77 lbs (35 kg).
- You cannot have untreated or active brain metastases that cause symptoms or need treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
This Phase 1 trial tests HF158K1 in people with advanced solid tumors that have HER2 protein. It aims to see if the drug can be given safely and learn how it works in people whose cancer shows HER2 on tumor testing.
This trial tests an experimental drug called HMPL-A830 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug can shrink tumors or slow their growth.
This early-phase trial tests a new investigational drug (HMPL-415S1) in people with advanced solid tumors that have limited treatment options. It aims to see how the drug is tolerated and whether it can shrink tumors, especially in cases with KRAS-pathway changes.
This trial tests a new drug called MG2512 for people with advanced solid tumors that have not responded to standard treatments or who cannot take standard therapy. The study aims to understand if MG2512 is safe and effective.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Hear when a new Solid Tumors, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.